Vor Bio (VOR): Price to Sales

Symbol and logo of brand Vor Biopharma, Inc. (VOR)

Vor Biopharma Inc. relies on third-party manufacturers for drug production and testing, creating a strong dependency on contractors. The P/S multiple trend on GURU.Markets demonstrates market expectations, where reflects the latest value of the metric. This is critical amid the fierce competition for leadership in cell therapy. Meanwhile, the business is shielded from macroeconomic crises due to the autonomy of its product cycles.

VOR: vorbio.com Market Cap to Revenue 07/04/2022 - 11/13/2026

Analytical breakdowns for Vor Bio (VOR)

- current price and projected stock value:
Price Chart vorbio.com|VOR - Price Target Chart
- stock exchange capitalization data:
Market Value Vor Bio|VOR - Total Company Value
- shareholders' equity book value data:
Accounting Value of a Share Vor Biopharma|VOR - Company Net Assets|Market Value to Book Value vorbio.com|VOR - Company Total Assets
- issuer credit burden and liquidity indicators:
Debt to Equity Vor Biopharma Inc.|VOR - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Vor Bio Inc.|VOR - Company Debts|Debts to Book Value Vor Bio|VOR - Company Long-Term Debt|Current Liabilities Vor Biopharma|Intermediate Coverage Ratio vorbio.com
- earnings and valuation multiples information:
VOR - Net Profit|Projected Future Earnings Vor Biopharma Inc.|VOR - Price to Earnings Ratio|Future Price to Earnings Multiple Vor Biopharma, Inc.|VOR - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Vor Bio|VOR - Operating profit EBITDA|Net earnings per share (EPS TTM) Vor Biopharma|VOR - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months vorbio.com|VOR - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Vor Biopharma Inc.
- sales revenue and business income indicators:
VOR - Company Revenue|Company Revenue Forecast vorbio.com|VOR - P/S Multiple|Forward Price-to-Revenue Multiple Vor Bio
Fundamental company analysis:VOR - vorbio.com
Product sample of Vor Biopharma Inc.

The P/S ratio measures a company's market value relative to its annual revenue, reflecting the extent to which an issuer's earnings are overvalued or undervalued in the eyes of investors. Analyzing the historical P/S trend allows for portfolio stress-testing by assessing the premium the market assigns to Vor Biopharma Inc. (VOR) and its breakthrough developments in genetic modification of stem cells to protect immunity during cancer therapy.

Competitors of Vor Biopharma Inc.

Price-to-Revenue Ratio TGTX (tgtherapeutics.com)|Price-to-Revenue Ratio Arcellx, Inc. ACLX|Disc Medicine Inc (IRON) - Price to Sales|SNDX - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio KURA (Kura)|ADCT (ADC Therapeutics) - Market Cap to Revenue|Foghorn Therapeutics Inc. - Market Capitalization-to-Revenue Ratio|NKTX (Nkarta Inc.) - P/S Multiple|Price-to-Revenue Ratio COEP|P/S Multiple ATNM|Price-to-Revenue Coefficient Estrella Immunopharma Corp|Price-to-Revenue Ratio CASI Pharmaceuticals, Inc. CASI|Marker Therapeutics Inc (MRKR) - Price to Sales|INAB - Price-to-Revenue Ratio|Price-to-Sales Ratio ERNA|GTBP: P/S Multiple|Aptose Biosciences - Market Capitalization-to-Revenue Ratio|BPTH (Bio-Path Holdings) - P/S Multiple|P/S Multiple meipharma.com|Price-to-Revenue Ratio Vincerx Pharma, Inc. (VINC)